CO2018000349A2 - Interleukin receptor peptide inhibitors 23 - Google Patents
Interleukin receptor peptide inhibitors 23Info
- Publication number
- CO2018000349A2 CO2018000349A2 CONC2018/0000349A CO2018000349A CO2018000349A2 CO 2018000349 A2 CO2018000349 A2 CO 2018000349A2 CO 2018000349 A CO2018000349 A CO 2018000349A CO 2018000349 A2 CO2018000349 A2 CO 2018000349A2
- Authority
- CO
- Colombia
- Prior art keywords
- amino acid
- peptide inhibitors
- receptor peptide
- interleukin receptor
- absent
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000002467 interleukin receptors Human genes 0.000 title 1
- 108010093036 interleukin receptors Proteins 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 6
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 239000000126 substance Chemical group 0.000 abstract 2
- 102100036672 Interleukin-23 receptor Human genes 0.000 abstract 1
- 101710195550 Interleukin-23 receptor Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona inhibidores peptídicos del receptor de interleucina 23, los cuales comprenden una secuencia de aminoácidos de fórmula (Xa): X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20 (Xa), en la que: X1, X2 y X3 son cualquier aminoácido o se encuentran ausentes; X4 es cualquier aminoácido o resto químico que pueda formar un enlace con X9; X5, X6, X7 y X8 son cualquier aminoácido;X9 es cualquier aminoácido o resto químico que pueda formar un enlace con X4; X10, X11, X12, X13, X14 y X15 son cualquier aminoácido; y X16, X17, X18, X19 y X20 son cualquier aminoácido o se encuentran ausentes; en donde los inhibidores peptídicos se ciclan mediante un enlace entre X4 y X9. Asimismo, se proporcionan polinucleótidos que codifican dichos inhibidores peptídicos, vectores que comprenden dichos polinucleótidos, y composiciones farmacéuticas que comprenden dichos inhibidores peptídicos.The present invention provides peptide inhibitors of the interleukin 23 receptor, which comprise an amino acid sequence of formula (Xa): X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 -X14-X15-X16-X17-X18-X19-X20 (Xa), in which: X1, X2 and X3 are any amino acid or are absent; X4 is any amino acid or chemical moiety that can form a bond with X9; X5, X6, X7 and X8 are any amino acid; X9 is any amino acid or chemical moiety that can form a bond with X4; X10, X11, X12, X13, X14 and X15 are any amino acid; and X16, X17, X18, X19 and X20 are any amino acid or are absent; wherein the peptide inhibitors are cycled through a link between X4 and X9. Likewise, polynucleotides encoding said peptide inhibitors, vectors comprising said polynucleotides, and pharmaceutical compositions comprising said peptide inhibitors are provided.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2015/040658 WO2016011208A1 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US14/800,627 US9624268B2 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US201562264820P | 2015-12-08 | 2015-12-08 | |
| US201662281123P | 2016-01-20 | 2016-01-20 | |
| PCT/US2016/042680 WO2017011820A2 (en) | 2015-07-15 | 2016-07-15 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018000349A2 true CO2018000349A2 (en) | 2018-07-10 |
Family
ID=57757647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0000349A CO2018000349A2 (en) | 2015-07-15 | 2018-01-15 | Interleukin receptor peptide inhibitors 23 |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP3341011A4 (en) |
| JP (1) | JP6858174B2 (en) |
| KR (1) | KR102513978B1 (en) |
| CN (1) | CN108348580B (en) |
| AU (1) | AU2016293619B2 (en) |
| BR (1) | BR112018000691A2 (en) |
| CA (1) | CA2991984A1 (en) |
| CL (3) | CL2018000128A1 (en) |
| CO (1) | CO2018000349A2 (en) |
| CR (1) | CR20180029A (en) |
| DO (1) | DOP2018000010A (en) |
| EA (1) | EA035733B9 (en) |
| EC (1) | ECSP18002929A (en) |
| HK (1) | HK1257747A1 (en) |
| IL (1) | IL256827A (en) |
| MX (1) | MX384213B (en) |
| NI (1) | NI201800008A (en) |
| PE (1) | PE20180571A1 (en) |
| PH (1) | PH12018500086A1 (en) |
| SG (1) | SG10201912066SA (en) |
| SV (1) | SV2018005614A (en) |
| UA (1) | UA123772C2 (en) |
| WO (1) | WO2017011820A2 (en) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ702747A (en) | 2012-06-13 | 2017-03-31 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
| HRP20211911T1 (en) | 2013-03-15 | 2022-03-18 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses therof |
| LT2986610T (en) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3960754A3 (en) | 2014-05-16 | 2022-07-06 | Protagonist Therapeutics, Inc. | Alpha4beta7 integrin thioether peptide antagonists |
| AU2015289642B2 (en) | 2014-07-17 | 2021-02-25 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
| MX391184B (en) | 2014-10-01 | 2025-03-19 | Protagonist Therapeutics Inc | NOVEL MONOMERIC AND DIMERIC a4ß7 PEPTIDE ANTAGONISTS. |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
| SG10201913036RA (en) | 2015-02-20 | 2020-02-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
| WO2018136646A1 (en) | 2017-01-18 | 2018-07-26 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| EP4501952A3 (en) | 2018-02-08 | 2025-04-16 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP3788046B1 (en) | 2018-05-04 | 2025-12-10 | Incyte Corporation | Salts of an fgfr inhibitor |
| EP4309737A3 (en) | 2018-05-04 | 2024-03-27 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| US20200040037A1 (en) * | 2018-07-12 | 2020-02-06 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| CN110015978B (en) * | 2019-04-29 | 2021-03-19 | 康化（上海）新药研发有限公司 | Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine |
| JP7736577B2 (en) * | 2019-07-01 | 2025-09-09 | バリター，インコーポレイティド | Hydrophilic linkers for multivalent peptide conjugates |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3146390A1 (en) | 2019-07-10 | 2021-01-14 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CR20220169A (en) | 2019-10-14 | 2022-10-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3819307A1 (en) * | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR20220131900A (en) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Derivatives of FGFR inhibitors |
| TWI882061B (en) * | 2020-01-15 | 2025-05-01 | 美商健生生物科技公司 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US12018057B2 (en) | 2020-01-15 | 2024-06-25 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN115916810A (en) * | 2020-06-29 | 2023-04-04 | 华盛顿大学 | Human IL23 receptor binding polypeptide |
| JP2023542867A (en) | 2020-09-11 | 2023-10-12 | グリンプス バイオ， インコーポレイテッド | In vitro protease activity detection for disease detection/diagnosis, staging, monitoring and treatment |
| JP2023145581A (en) * | 2020-11-20 | 2023-10-11 | ヤンセン ファーマシューティカ エヌ．ベー． | Compositions of peptide inhibitors of interleukin-23 receptors |
| PE20240631A1 (en) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | COMPOSITIONS OF PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| AR126101A1 (en) | 2021-06-09 | 2023-09-13 | Incyte Corp | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| AR126102A1 (en) | 2021-06-09 | 2023-09-13 | Incyte Corp | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| US20240409598A1 (en) * | 2021-07-14 | 2024-12-12 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor |
| EP4370146A4 (en) | 2021-07-14 | 2025-05-21 | Janssen Biotech, Inc. | LIPIDATED PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR |
| JP2024525723A (en) * | 2021-07-14 | 2024-07-12 | ヤンセン バイオテツク，インコーポレーテツド | Bicyclic peptide inhibitors of the interleukin-23 receptor - Patents.com |
| CN118354781A (en) | 2021-12-01 | 2024-07-16 | 西兰制药公司 | Peptide inhibitors of interleukin-23 receptor |
| EP4490308A2 (en) * | 2022-03-09 | 2025-01-15 | Sunbird Bio, Inc. | Fluorogenic substrates for aminopeptidase detection in biofluids |
| CN114751962B (en) * | 2022-03-17 | 2023-11-07 | 北京大学 | Staple peptide, preparation method and pharmaceutical application thereof |
| AU2023300411A1 (en) | 2022-06-30 | 2025-02-13 | Sanofi | New peptides as selective il-23 receptor antagonists |
| WO2024110477A2 (en) * | 2022-11-21 | 2024-05-30 | Janssen Pharmaceutica Nv | Synthesis of a cyclic peptide |
| WO2024155551A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Polycyclic peptide inhibitors of interleukin-23 receptor |
| WO2024155547A2 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Peptide inhibitors of interleukin-23 receptor |
| KR20250139359A (en) | 2023-01-31 | 2025-09-23 | 얀센 파마슈티카 엔브이 | Method for preparing a crystalline peptide inhibitor of interleukin-23 receptor |
| WO2024227437A1 (en) * | 2023-05-04 | 2024-11-07 | 西藏海思科制药有限公司 | Preparation of peptide inhibitor of interleukin-23 receptor and use thereof |
| EP4471049A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| EP4471048A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2025051912A1 (en) | 2023-09-08 | 2025-03-13 | Sanofi | New peptides as selective il-23 receptor inhibitors |
| WO2025051920A1 (en) | 2023-09-08 | 2025-03-13 | Sanofi | New peptides as selective il-23 receptor inhibitors |
| WO2026013260A1 (en) | 2024-07-12 | 2026-01-15 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5942492A (en) * | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| GEP20135944B (en) | 2007-02-15 | 2013-10-25 | Indiana Unversity Research And Tech Corporation | Glucagon/glp-1 receptor co-agonists |
| EP2288621A4 (en) * | 2007-07-06 | 2012-01-04 | Valorisation Hsj Soc En Commandite | Il-23 receptor antagonists and uses thereof |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| US10416172B2 (en) * | 2010-03-31 | 2019-09-17 | Medical Diagnostic Laboratories, Llc | Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling |
| US9169292B2 (en) * | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US8946150B2 (en) * | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| CA2926685A1 (en) * | 2013-10-09 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| AU2015289642B2 (en) * | 2014-07-17 | 2021-02-25 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
-
2016
- 2016-07-15 CN CN201680049562.2A patent/CN108348580B/en active Active
- 2016-07-15 KR KR1020187004612A patent/KR102513978B1/en active Active
- 2016-07-15 BR BR112018000691A patent/BR112018000691A2/en not_active IP Right Cessation
- 2016-07-15 EA EA201890325A patent/EA035733B9/en not_active IP Right Cessation
- 2016-07-15 PE PE2018000053A patent/PE20180571A1/en unknown
- 2016-07-15 HK HK19100122.0A patent/HK1257747A1/en unknown
- 2016-07-15 MX MX2018000542A patent/MX384213B/en unknown
- 2016-07-15 JP JP2018501178A patent/JP6858174B2/en active Active
- 2016-07-15 CA CA2991984A patent/CA2991984A1/en active Pending
- 2016-07-15 EP EP16825301.1A patent/EP3341011A4/en not_active Withdrawn
- 2016-07-15 SG SG10201912066SA patent/SG10201912066SA/en unknown
- 2016-07-15 AU AU2016293619A patent/AU2016293619B2/en active Active
- 2016-07-15 UA UAA201801482A patent/UA123772C2/en unknown
- 2016-07-15 CR CR20180029A patent/CR20180029A/en unknown
- 2016-07-15 WO PCT/US2016/042680 patent/WO2017011820A2/en not_active Ceased
-
2018
- 2018-01-09 PH PH12018500086A patent/PH12018500086A1/en unknown
- 2018-01-10 IL IL256827A patent/IL256827A/en unknown
- 2018-01-10 DO DO2018000010A patent/DOP2018000010A/en unknown
- 2018-01-11 NI NI201800008A patent/NI201800008A/en unknown
- 2018-01-15 CO CONC2018/0000349A patent/CO2018000349A2/en unknown
- 2018-01-15 EC ECIEPI20182929A patent/ECSP18002929A/en unknown
- 2018-01-15 CL CL2018000128A patent/CL2018000128A1/en unknown
- 2018-01-15 SV SV2018005614A patent/SV2018005614A/en unknown
- 2018-11-22 CL CL2018003322A patent/CL2018003322A1/en unknown
-
2021
- 2021-02-09 CL CL2021000343A patent/CL2021000343A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018000349A2 (en) | Interleukin receptor peptide inhibitors 23 | |
| MX2018015699A (en) | CANNABINOID FORMULATIONS. | |
| PE20160045A1 (en) | SOLUBLE AND STABILIZED RESPIRATORY SYNCITIAL VIRUS (RSV) PREFUSION POLYPEPTIDES F | |
| CY1121891T1 (en) | GENETICALLY MODIFIED PHENYLALANINE-AMMONIA LYASE POLYPEPTIDES | |
| CU20180062A7 (en) | HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES | |
| CO2018005525A2 (en) | Aqueous pharmaceutical formulation of the anti-pd-l1 avelumab antibody | |
| MX2019013123A (en) | Oral dosing of glp-1 compounds. | |
| CL2011003147A1 (en) | Compounds derived from n- (1-4- (1h-pyrazol-5-yl) phthalazine-1-yl) piperidine-4-yl) benzamide; pharmaceutical composition that contains them, useful as antagonist of the hedgehog trajectory, in the treatment of cancer. | |
| DOP2016000042A (en) | ANTIBODIES AGAINST THE TYPE 1 (PAI-1) PLASMINOGEN ACTIVATOR INHIBITOR AND USES OF THE SAME | |
| MX374483B (en) | ANTIBODY-FYNOMER CONJUGATES. | |
| CL2015002566A1 (en) | Drip chamber with integrated optics | |
| CL2018003319A1 (en) | Mic-1 compounds and uses of these. | |
| JOP20200039A1 (en) | Pharmaceutical preparation containing recombinant HCG | |
| UY37456A (en) | IMMUNOGLOBULINAS AND ITS USES | |
| MX2016015006A (en) | Antibody formulation. | |
| MX2016012103A (en) | AGONISTS OF THE MUSCARINIC RECEIVER. | |
| CL2017001483A1 (en) | Fixed ratio formulation of insulin glargine / lixisenatide | |
| CY1123738T1 (en) | ADDITIVES THAT ENHANCE THE BIOACTIVITY OF GONADOTROPINS | |
| AR101742A1 (en) | CALCITONINE AND AMILINE RECEIVER AGONIST | |
| MX387228B (en) | PYRAZOLE COMPOUNDS AS FOLLICLE-STIMULATING HORMONE RECEPTOR MODULATORS AND THEIR USES. | |
| UA116431C2 (en) | COMPOSITION FOR PREVENTION OF INFECTION MYCOPLASMA SPP. | |
| MX389026B (en) | A PHARMACEUTICAL COMPOSITION AND ITS USE. | |
| CL2017001129S1 (en) | Dental positioner (divisional application 18-2016) | |
| BR112015020079A2 (en) | oral care compositions | |
| EA201790552A1 (en) | APPLICATION OF ELSIGLUTID FOR THE TREATMENT OF MUSOCITE OF GASTROINTESTINAL TRACT, INCLUDING CHIOTHERAPY-INDUCED DIARRHEA |